FY2025 EPS Estimates for NovoCure Lifted by Leerink Partnrs

NovoCure Limited (NASDAQ:NVCR) – Equities research analysts at Leerink Partnrs lifted their FY2025 EPS estimates for NovoCure in a research note issued to investors on Monday, December 2nd. Leerink Partnrs analyst J. Chang now forecasts that the medical equipment provider will post earnings of ($1.92) per share for the year, up from their prior estimate of ($1.93). The consensus estimate for NovoCure’s current full-year earnings is ($1.31) per share.

A number of other research analysts have also recently weighed in on NVCR. HC Wainwright restated a “buy” rating and issued a $38.00 price objective (up previously from $30.00) on shares of NovoCure in a report on Monday. Evercore ISI raised NovoCure from an “in-line” rating to an “outperform” rating and upped their price objective for the stock from $18.00 to $30.00 in a research report on Monday. Finally, Wedbush reiterated a “neutral” rating and issued a $29.00 target price (up from $24.00) on shares of NovoCure in a report on Monday. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $30.33.

NovoCure Stock Down 9.0 %

Shares of NASDAQ NVCR opened at $26.60 on Thursday. The company has a quick ratio of 1.44, a current ratio of 1.49 and a debt-to-equity ratio of 0.27. The business’s 50 day moving average is $17.68 and its two-hundred day moving average is $18.64. NovoCure has a 52-week low of $11.66 and a 52-week high of $32.60. The firm has a market cap of $2.88 billion, a price-to-earnings ratio of -19.00 and a beta of 0.75.

NovoCure (NASDAQ:NVCR) last issued its earnings results on Wednesday, October 30th. The medical equipment provider reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.06. The company had revenue of $155.10 million for the quarter, compared to the consensus estimate of $143.95 million. NovoCure had a negative net margin of 25.93% and a negative return on equity of 41.48%. NovoCure’s quarterly revenue was up 21.8% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.46) earnings per share.

Institutional Investors Weigh In On NovoCure

Several institutional investors and hedge funds have recently made changes to their positions in the business. Ridgewood Investments LLC acquired a new position in NovoCure in the 2nd quarter valued at about $28,000. Signaturefd LLC lifted its stake in shares of NovoCure by 61.7% during the second quarter. Signaturefd LLC now owns 1,644 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 627 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of NovoCure during the second quarter valued at approximately $34,000. Fifth Third Bancorp acquired a new stake in NovoCure during the second quarter worth approximately $43,000. Finally, Nisa Investment Advisors LLC purchased a new stake in NovoCure in the 2nd quarter worth approximately $48,000. 84.61% of the stock is currently owned by hedge funds and other institutional investors.

NovoCure Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua.